ClinicalTrials.gg

Program

Lymphodepleting chemotherapy

Its studies are mostly in Small Cell Lung Carcinoma · Neoplasms · Carcinoma, Ovarian Epithelial, led by Beijing Biotech.

Furthest: phase 2, since Mar 14, 20263 company-led studies, 3 open or runningNext primary completion: Feb 14, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Beijing Biotech33 open or runningphase 2since Mar 14, 2026Mar 14, 2026Feb 14, 2027phase 2 · NCT07744256

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 14, 2026First studies: 2 phase 2 studiesFirst studyNCT07480954, NCT07510828
  2. Jul 30, 2026Phase 2 study in Small Cell Lung CarcinomaNCT07744256 · 60 planned · China

Ahead

  1. Feb 14, 2027Primary completion: phase 2 study in Small Cell Lung CarcinomaNCT07744256
  2. Feb 17, 2027Primary completion: phase 2 study in Carcinoma, Ovarian EpithelialNCT07480954
  3. Mar 14, 2027Primary completion: phase 2 study in NeoplasmsNCT07510828

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07744256Small Cell Lung Carcinoma · China2RecruitingFeb 14, 202760
NCT07510828Neoplasms · China2RecruitingMar 14, 202760
NCT07480954Carcinoma, Ovarian Epithelial · China2RecruitingFeb 17, 202736

How it is read

Names in the registry

  • “Lymphodepleting chemotherapy”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.